Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences Inc (NQ: KZR )

5.480 USD UNCHANGED
Streaming Delayed Price Updated: 5:05 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 5.480
Bid (Size) 4.800 (18)
Ask (Size) 6.450 (3)
Prev. Close 5.480
Today's Range 5.480 - 5.480
52wk Range 2.180 - 9.790
Shares Outstanding 18,321,522
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Kezar Life Sciences to Participate at Cowen 41st Annual Virtual Health Care Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief... 
From Business Wire News Releases
Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Chief... 
From Business Wire News Releases

Performance

YTD
+3.79%
+3.79%
1 Month
+3.20%
+3.20%
3 Month
-16.72%
-16.72%
6 Month
+12.76%
+12.76%
1 Year
+11.84%
+11.84%

More News

Read More
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
From Business Wire News Releases
Kezar Life Sciences Added to the Nasdaq Biotechnology Index
From Business Wire News Releases
Kezar Life Sciences to Present During Upcoming Virtual Investor Conferences
From Business Wire News Releases
Kezar Life Sciences Reports Third-Quarter 2020 Financial Results and Provides Business Updates
From Business Wire News Releases
12 Health Care Stocks Moving In Tuesday's After-Market Session
Tags Market News ONTX TLMD
From Benzinga
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020
From Business Wire News Releases
Look Under The Hood: IBB Has 19% Upside
Tags ETFs
From ETF Channel
Kezar Life Sciences Announces Orphan Drug Designations for KZR-616 for the Treatment of Polymyositis and Dermatomyositis
From Business Wire News Releases
Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]